SCHEMBL7103339

SCHEMBL7103339

CCS(=O)(=O)NC(C(=O)NCc1ccc(O)c(OC)c1)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
CYP1A2 P05177 4/20 0.51
CYP3A4 P08684 4/20 0.51
CYP2D6 P10635 3/20 0.51
CYP2C9 P11712 3/20 0.51
CYP2C19 P33261 3/20 0.51
ALDH1A1 P00352 3/20 0.51
BLM P54132 2/20 0.51
PMP22 Q01453 2/20 0.51
ALOX15 P16050 2/20 0.51
HPGD P15428 1/20 0.51
POLB P06746 1/20 0.51
TSHR P16473 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TRPV1 Q8NER1 4/20 0.48
MAPK1 P28482 2/20 0.48
KDM1A O60341 1/20 0.48
NR1I2 O75469 1/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7103335 1.00 MEN1 (0.57) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL6553382 0.89 SMN1; SMN2 (0.50) MEN1KMT2ALMNAALOX5SMN1; SMN2
SCHEMBL6553375 0.89 SMN1; SMN2 (0.50) MEN1KMT2ALMNAALOX5SMN1; SMN2
SCHEMBL17476717 0.82 MEN1 (0.67) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7015776 0.82 RAB9A (0.57) MEN1KMT2ACYP3A4ALDH1A1ALOX15
SCHEMBL7015773 0.82 RAB9A (0.57) MEN1KMT2ACYP3A4ALDH1A1ALOX15
SCHEMBL5197621 0.80 CYP1A2 (0.59) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL17488471 0.80 MEN1 (0.63) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL4947604 0.79 CYP3A4 (0.60) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL17667848 0.79 CYP3A4 (0.60) MEN1KMT2ACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030224940-A1 Alpha-sulfin-and alpha-sulfonamino acid amide derivatives SYNGENTA CROP PROTECTION, INC. 2003-12-04 US disclosed
CN-1422251-A Novel alpha-sulfin-and alpha-sulfonamino acid amide derivatives SYNGENTA PARTICIPATIONS AG (CH) 2003-06-04 CN disclosed
EP-1272461-A1 ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDE DERIVATIVES Syngenta Participations AG (CH) 2003-01-08 EP disclosed
WO-2001079160-A1 ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030224940-A1 Alpha-sulfin-and alpha-sulfonamino acid amide derivatives STS, ARSA, SULT2A1 MEN1 2787/4885KMT2A 1753/4885CYP1A2 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.